Marburg, January 3, 2019, AGCT closes financing round to accelerate revolutionary assay technology development for oncology market    AGCT announces the closing of a substantial financing round with existing investors and two investment companies. The financing followed a technology milestone achievement demonstrating the performance of AGCT’s proprietary cyberPCR technology. cyberPCR is a novel PCR-based method that AGCT believes has the power to significantly improve the early detection of circulating tumor DNA from cancer liquid biopsies over existing assay technologies. The unique advantage of cyberPCR is the exclusive amplification of tumor-derived DNASEE DETAILS <span class="more-link-image...